Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-18
2007-12-18
Richter, Johann (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254060, C514S254070, C544S187000, C544S362000, C544S368000, C544S370000, C544S371000
Reexamination Certificate
active
09928122
ABSTRACT:
Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.
REFERENCES:
patent: 3994890 (1976-11-01), Fujimura et al.
patent: 4500525 (1985-02-01), Winters et al.
patent: 5264576 (1993-11-01), Shutske et al.
patent: 5599815 (1997-02-01), Fukuda et al.
patent: 5776718 (1998-07-01), Palmer et al.
patent: 5830850 (1998-11-01), Gelb et al.
patent: 5976858 (1999-11-01), Palmer et al.
patent: 6020336 (2000-02-01), Lavielle et al.
patent: 6030946 (2000-02-01), Klaus et al.
patent: 6046205 (2000-04-01), Lavielle et al.
patent: 6214813 (2001-04-01), Zhang et al.
patent: 6287840 (2001-09-01), Palmer et al.
patent: 2002/0040020 (2002-04-01), Breitenbucher et al.
patent: 199714432 (1997-01-01), None
patent: 0254241 (1988-01-01), None
patent: 382637 (1993-07-01), None
patent: 502786 (1996-04-01), None
patent: 0747049 (1996-12-01), None
patent: 0902027 (1999-03-01), None
patent: 655248 (1999-09-01), None
patent: 1489280 (1977-10-01), None
patent: 50116470 (1975-09-01), None
patent: 52014765 (1977-02-01), None
patent: WO 95/23222 (1995-08-01), None
patent: WO 96/30353 (1996-10-01), None
patent: WO 97/21439 (1997-06-01), None
patent: WO 97/40068 (1997-10-01), None
patent: WO 9856785 (1998-12-01), None
patent: WO 99/24460 (1999-05-01), None
patent: WO 99/48911 (1999-09-01), None
patent: WO 99/58153 (1999-11-01), None
patent: WO 00/49008 (2000-08-01), None
patent: WO 00/51998 (2000-09-01), None
patent: WO 00/55144 (2000-09-01), None
patent: WO 01/09110 (2001-02-01), None
patent: WO 01/19796 (2001-03-01), None
patent: WO 01/40204 (2001-06-01), None
Paluchowska et al., Chemical Abstracts, vol. 134:36671, 2000.
Paluchowska et al., Chemical Abstracts, vol. 132:245821, 1999.
Lavielle et al., Chemical Abstracts, vol. 130:237561, 1999.
Andronati et al., Chemical Abstracts, vol. 130:276243, 1999.
Fukuda et al., Chemical Abstracts, vol. 123:83356, 1995.
Palmer, J. T. et al.; “Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors”; J. Med. Chem. (1995) 38(17):3193-3196.
Bromme, D. et al.; “Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors”; Biochem. J. (1996) 315:85-89.
McGrath, M.E. et al.; “Crystal structure of human cathepsin S”; Protein Science (1998) 7:1294-1302.
Nerenberg, J. B. et al.: “Design and Synthesis of N-Alkylated Saccharins as Selective a-1A Adrenergic Receptor Antagonists”; Bioorg. Med. Chem Lett. (1998) 8:2467-2472.
Honey, K. et al.; “Role of Lysosomal Cysteine Proteinases in Antigen Presentation to CD4 T Cells”; Inflammation Research (2001) Sup.3, vol. 50, pS159 abstr. Oct. 2001.
Li, W. et al.; “Tissue Specific Expression of Cathepsins and Antigen Presentation”; Inflammation Research (2001) Sup 3, vol. 50 p. S159 abstr. Oct. 2002.
Magill, C. et al.; “Cysteine Proteases in Antigen Presentation and Models of Inflammation”; Inflammation Research (2001) Sup 3, vol. 50, p. S159, abstr. Oct. 2003.
Allen, E.M. et al.; “Reversible Cathepsin S (CATS) Inhibitors Block Invariant Chain Degradation Both In Vitro and In Vivo”; Inflammation Research (2001) Sup. 3, vol. 50, p. S159, abstr. Oct. 2004.
Podolin, P. L. et al.; “Inhibition of Cathepsin S Blocks Invariant Chain Processing and Antigen-Induced Proliferation in Vitro, and Reduces the Severity of Collagen-Induced Arthritis in Vivo”; Inflammation Research (2001) Sup. 3, vol. 50, p. S159, abstr. Oct. 2005.
Spero, D. et al.; “Design and Synthesis of Novel Cathepsin S Inhibitors”; Inflammation Research (2001) Sup. 3, vol. 50, p. S206, abstr. 079.
Andronati, S.A. et al.: “Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]1,2-dihydro-3H-1,4-benzodiazepin-2-ones and1H-indazoles and their affinity for benzodiazepine receptors”; Chemical Abstracts No. (CAN) 122:314528; (1994) 8:126-131.
Bromme, D, et al.; “High level expression and crystallization of recombinant human cathepsin S”; Protein Science (1996) 5:789-791.
Kirschke, H. et al.; “Cathepsin S”; Handbook of Proteolytic Enzymes; Barett, A.J.; Rawlings, N.D.; Woessner, J.F., Editors, Academic Press (1998) 621-624.
Nakagawa, T.Y. et al.; “Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis Cathepsin S Null Mice”; Immunity (1999) 10:207-217.
Riese, R.J. et al.; “Cathepsin S Activity Regulates Antigen Presentation and Immunity”; J. Clin. Invest. (1998) 101(11):2351-2363.
Shi, G.P., et al.; “Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development”; Immunity (1999) 10:197-206.
Singh, P., et al.; “Quantitative Structure-Activity Relationship Studies on a New Class of -Antihypertensive Agents: Derivatives of 3-Aryl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine”; Quant. Struct.-Act. Relat. (1990) 9:29-32.
Winters, G. et al.; “Synthesis in Vitro [3H]Prazosin Displacement and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a New Class of Antihypertensive”; J. Med. Chem. (1985) 28(7):934-940.
Andronati, S., et al. “Synthesis of 3-aryl-1-piperzainyl)butyl in dazole derivatives and their affinity to 5-HT1a serotonin and dopamine D1 receptors”, Database CA 'Online! Chemical Abstracts Service, STN database accession No. 130:276243, XP002193795 abstract, (1999), 54(2), 99-101.
Fujimura, Y. et al. “Indazole derivatives”, Database CA 'Online! Chemical Abstracts Service, STN database accession No. 87:53281, XP002193796 abstract, (Feb. 3, 1977) relating to JP 52014765 (Chugai Pharmaceutical Co., Ltd.).
Fujimura, Y., et al. “Indazole derivatives”, Database CA 'Online! Chemical Abstracts Service, STN database accession No. 84:59450, XP002193797 abstract, (Sep. 11, 1975) relating to JP 50116470 (Chugai Pharmaceutical Co., Ltd.).
Nakatsuka, M. et al. “Preparation of pyrazole derivatives as immunosuppressants”, Database CA 'Online! Chemical Abstracts Service, STN database accession No. 130:52417, XP002193692 abstract, (Dec. 17, 1998) relating to WO9856785 (Sumitomo Pharmaceuticals Co., Ltd.).
PCT International Search Report, PCT/US01/25289, Apr. 12, 2002.
Leroy, et al, Ashley Publications Ltd., Expert Opin. Ther. Patents (2004) 14(3): 301-311, “Cathepsin S inhibitors”.
Chapman, H.A. et al., “Emerging Roles for Cysteine Proteases in Human Biology”; Annu. Rev. Physiol. (1997) 59:63-88.
Chapman, H.A. et al., “Endosomal Proteolysis and MHC Class II Function”; Curr. Opin. in Immunol. (1998) 10:93-102.
Gaga, et al., “Eosinophil Activation and T Lymphocyte Infiltration in Allergin-induced Late Phase Skin Reactions and Classical Delayed-Type Hypersensitivity” Journal. Immun. (1991) 147:816-822.
Maurer, D. et al., “Fce Receptor I on Dendritic Cells Delivers IgE-Bound Multivalent Antigens into a Cathepsin S-Dependent Pathway of MHC Class II Presentation” J. Immunol. (1998) 161:2731-2739.
Nakagawa, T.Y. et al., “Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice”; Immunity (1999) 10:207-217.
Nakagawa, T.Y. et al., “The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation” Immunological Rev. (1999) 172:121-129.
Paluchowska, et al., Polish J. Pharmacology 51(5), 415-421 (1999) Structure-Acitivty Relationship Studies of CNS Agents part 40. “Effect of the Amide Fragment on 5-HT1AReceptor Activity of Some Analogs of MP 3022”.
Paluchowska, et al., Polish J. Pharmacology 52(3), 209-216 (2000) “Influence of the Aliphatic Spacer Length on the 5-HT1AReceptor Activity of New Arylpiperazines with an Indazole System”.
Riese, R.J. et al., Cathepsins and Compartmentalization in Antigen Presentation; Curr. Opin. Immunol. (20
Beavers Mary Pat
Breitenbucher J. Guy
Cai Hui
Edwards James P.
Grice Cheryl A.
Ortho -McNeil Pharmaceutical, Inc.
Richter Johann
Sackey Ebenezer
LandOfFree
Substituted pyrazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857360